Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, UBS Group Analyst Says

Elanco Animal Health (NYSE:ELAN) had its price target hoisted by UBS Group from $27.00 to $30.00 in a report issued on Thursday,MarketScreener reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective indicates a potential upside of 24.82% from the company’s previous close.

Other analysts have also issued research reports about the company. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their target price for the company from $24.00 to $30.00 in a report on Thursday, January 22nd. Morgan Stanley raised their price objective on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 18th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. Finally, Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.44.

Elanco Animal Health Trading Down 0.7%

Shares of NYSE ELAN traded down $0.17 during mid-day trading on Thursday, hitting $24.04. 39,146 shares of the company traded hands, compared to its average volume of 4,554,182. The business has a 50 day moving average of $22.99 and a two-hundred day moving average of $20.24. The stock has a market capitalization of $11.94 billion, a price-to-earnings ratio of 402.40, a PEG ratio of 3.35 and a beta of 1.87. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $25.29. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the firm earned $0.13 earnings per share. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company’s stock in a transaction on Friday, December 12th. The shares were acquired at an average cost of $21.30 per share, with a total value of $213,000.00. Following the completion of the acquisition, the director directly owned 131,773 shares in the company, valued at $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares in the company, valued at $3,632,250. This represents a 15.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 43,450 shares of company stock worth $937,883 over the last 90 days. 0.89% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA increased its position in shares of Elanco Animal Health by 3.1% during the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after buying an additional 1,543,279 shares during the period. Vanguard Group Inc. raised its position in Elanco Animal Health by 1.6% during the third quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock valued at $978,536,000 after purchasing an additional 759,623 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Elanco Animal Health by 8.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock valued at $497,610,000 after buying an additional 1,962,276 shares in the last quarter. UBS Group AG raised its holdings in shares of Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares in the last quarter. Finally, Brandes Investment Partners LP lifted its position in Elanco Animal Health by 11.3% in the 2nd quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock worth $115,673,000 after buying an additional 820,901 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.